Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the prese...
Publications
2 shownDurable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-relate...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 2,780
- Institution
- Novartis (United States)
External Links
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.